Reported Earnings • May 19
Full year 2026 earnings released: JP¥48.17 loss per share (vs JP¥63.35 loss in FY 2025) Full year 2026 results: JP¥48.17 loss per share (improved from JP¥63.35 loss in FY 2025). Revenue: JP¥135.0m (up 13% from FY 2025). Net loss: JP¥718.0m (loss narrowed 21% from FY 2025). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Annuncio • May 14
Perseus Proteomics Inc., Annual General Meeting, Jun 24, 2026 Perseus Proteomics Inc., Annual General Meeting, Jun 24, 2026. Reported Earnings • Feb 16
Third quarter 2026 earnings released: JP¥11.39 loss per share (vs JP¥13.50 loss in 3Q 2025) Third quarter 2026 results: JP¥11.39 loss per share (improved from JP¥13.50 loss in 3Q 2025). Revenue: JP¥43.0m (up 82% from 3Q 2025). Net loss: JP¥168.0m (loss narrowed 16% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Annuncio • Jan 05
Perseus Proteomics Inc. announced that it has received ¥2.9808 million in funding from Macquarie Bank Limited On January 5, 2026, Perseus Proteomics Inc. closed the transaction. Annuncio • Dec 19
Perseus Proteomics Inc. announced that it expects to receive ¥2.9808 million in funding from Macquarie Group Limited Perseus Proteomics Inc. announced a private placement of 36,800 29th stock acquisition rights at ¥81 per stock acquisition right for gross proceeds of ¥2,980,800 on December 17, 2025. The transaction included participation from new investor Macquarie Group Limited. The potential shares from the issuance of stock acquisition rights will be 3,680,000 shares. The initial exercise price of stock acquisition rights ¥255 for a period from January 6, 2026 to January 5, 2028. The transaction will happen through third party allocation. The issue date for stock acquisition rights will be January 5, 2026. The transaction has been approved at board of directors’ meeting of the company. New Risk • Dec 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 14% per year over the past 5 years. Revenue is less than US$1m (JP¥121m revenue, or US$777k). Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Market cap is less than US$100m (JP¥3.91b market cap, or US$25.1m). Annuncio • Dec 12
Perseus Proteomics Inc. to Report Q3, 2026 Results on Feb 13, 2026 Perseus Proteomics Inc. announced that they will report Q3, 2026 results on Feb 13, 2026 Annuncio • Sep 02
Perseus Proteomics Inc. to Report Q2, 2026 Results on Nov 14, 2025 Perseus Proteomics Inc. announced that they will report Q2, 2026 results on Nov 14, 2025 Reported Earnings • Aug 16
First quarter 2026 earnings released: JP¥11.93 loss per share (vs JP¥17.95 loss in 1Q 2025) First quarter 2026 results: JP¥11.93 loss per share (improved from JP¥17.95 loss in 1Q 2025). Net loss: JP¥176.0m (loss narrowed 29% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 4% per year. Board Change • Jul 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. Executive Officer, Head of R&D Dept., Head of Business Development Dept. and Director Shinji Hagiwara was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annuncio • Jun 27
Perseus Proteomics Inc. to Report Q1, 2026 Results on Aug 14, 2025 Perseus Proteomics Inc. announced that they will report Q1, 2026 results on Aug 14, 2025 Reported Earnings • May 21
Full year 2025 earnings released: JP¥63.35 loss per share (vs JP¥93.65 loss in FY 2024) Full year 2025 results: JP¥63.35 loss per share (improved from JP¥93.65 loss in FY 2024). Net loss: JP¥904.0m (loss narrowed 18% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Annuncio • May 15
Perseus Proteomics Inc., Annual General Meeting, Jun 27, 2025 Perseus Proteomics Inc., Annual General Meeting, Jun 27, 2025. Annuncio • Mar 18
Perseus Proteomics Inc. Announces PPMX-T003 Notice on Completion of Clinical Study Report of Phase I Clinical Trial Among Polycythemia Vera Patients Perseus Proteomics Inc. announced that it has completed the clinical study report (CSR) of the Phase I clinical trial of an anti-transferrin receptor 1 antibody, PPMX-T003 ("the Phase I"), among polycythemia vera ("PV") patients. The Phase I was conducted with six subjects suffering from PV, a disease characterized by abnormal increase in red blood cells to evaluate safety and pharmacokinetics of PPMX-T003, as well as to confirm its efficacy as secondary endpoints. As a result, no serious adverse events of concern regarding the safety of PPMX-T001 were confirmed and efficacy was indicated with RBC parameters including hematocrit and hemoglobin. Also, a 12-week period without the need for phlebotomy was achieved in 5 subjects except for the sixth subject whose tests were terminated due to personal reasons. There is no impact on the business result for the fiscal year 2025/3. There is no impact on The business result for the fiscal year 2022/3. There is no effect on the business result for the Fiscal year 2025/3. Annuncio • Mar 01
Perseus Proteomics Inc. to Report Fiscal Year 2025 Results on May 15, 2025 Perseus Proteomics Inc. announced that they will report fiscal year 2025 results on May 15, 2025 Reported Earnings • Feb 16
Third quarter 2025 earnings released: JP¥13.50 loss per share (vs JP¥22.57 loss in 3Q 2024) Third quarter 2025 results: JP¥13.50 loss per share (improved from JP¥22.57 loss in 3Q 2024). Net loss: JP¥199.0m (loss narrowed 25% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings. Annuncio • Jan 03
Perseus Proteomics Inc. to Report Q3, 2025 Results on Feb 14, 2025 Perseus Proteomics Inc. announced that they will report Q3, 2025 results on Feb 14, 2025 Annuncio • Dec 12
Perseus Proteomics Inc. Announces Extension of Investigator-Led Phase I/II Clinical Trial for Aggressive NK-cell Leukemia (ANKL) Perseus Proteomics Inc. announced that the period of investigator-led phase I/II clinical trial of PPMX-T003, an anti-transferrin receptor 1 antibody, for aggressive NK-cell leukemia has been extended until March 31, 2026. Facing challenges in subject registration due to the target being an exceptionally rare disease, the Company has been preparing for the extension of the clinical trial with the clinical trial coordinators and other related parties. Recently, the clinical trial coordinator determined that it would be difficult to complete the study by March 31, 2025. Thus, an extension of the trial period until March 31, 2026 has been registered with the jRCT (Japan Registry of Clinical Trials), a system for submitting and publicizing clinical research. The Company is closely examining the impact on the business results of the fiscal year ending March, 2025 as well as the following fiscal year and will disclose the results immediately. Annuncio • Sep 27
Perseus Proteomics Inc. Announces Registration of Patent Jointly Filed with Juntendo University Perseus Proteomics Inc. announced that a patent has been registered in Japan regarding PPMX-T003, an anti-transferrin receptor 1 antibody. This patent was jointly filed with the research group of Chief Professor Norio Komatsu at Faculty of Medicine and Senior Associate Professor Marito Araki at Graduate School of Medicine, Juntendo University (affiliations were at the time of application). Title of invention: THERAPEUTIC DRUG FOR POLYCYTHEMIA. Patent No.: JPB7560815. Registration date: September 25, 2024. This patent stipulates therapeutic applications of PPMX-T003 for polycythemia vera, among other various applications. The Company and the university have filed applications for patents in other major countries as well. The Company has been striving for strengthening intellectual property rights for a broad range of therapeutic applications of PPMX-T003. Substance patents of this antibody have been already registered and plural applications are under examination. There is no impact on the financial results for the fiscal year ending March 31, 2025. Annuncio • Aug 27
Perseus Proteomics Inc. to Report Q2, 2025 Results on Nov 14, 2024 Perseus Proteomics Inc. announced that they will report Q2, 2025 results on Nov 14, 2024 Reported Earnings • Aug 19
First quarter 2025 earnings released: JP¥15.77 loss per share (vs JP¥35.89 loss in 1Q 2024) First quarter 2025 results: JP¥15.77 loss per share (improved from JP¥35.89 loss in 1Q 2024). Net loss: JP¥219.0m (loss narrowed 48% from 1Q 2024). Reported Earnings • Jun 25
Full year 2024 earnings released: JP¥93.65 loss per share (vs JP¥66.84 loss in FY 2023) Full year 2024 results: JP¥93.65 loss per share (further deteriorated from JP¥66.84 loss in FY 2023). Net loss: JP¥1.10b (loss widened 41% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 23% per year whereas the company’s share price has fallen by 21% per year. Reported Earnings • May 21
Full year 2024 earnings released: JP¥93.65 loss per share (vs JP¥66.84 loss in FY 2023) Full year 2024 results: JP¥93.65 loss per share (further deteriorated from JP¥66.84 loss in FY 2023). Net loss: JP¥1.10b (loss widened 41% from FY 2023). Annuncio • May 17
Perseus Proteomics Inc., Annual General Meeting, Jun 20, 2024 Perseus Proteomics Inc., Annual General Meeting, Jun 20, 2024. Annuncio • May 11
Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera Perseus Proteomics Inc. announced that there will be a delay in the end of the Phase I clinical trial of PPMX-T003, an anti-transferrin receptor 1 (TfR1) antibody, among PV patients from the previous forecast of the end of June 2024 to the end of July 2024. This trial primarily investigates the safety and pharmacokinetics in administering PPMX-T003 to 6 patients suffering from PV, a disease characterized by excess increase in red blood cells (RBCs). The secondary purpose is to confirm the therapeutic effects. The tests of the 5 patients have already ended and the company has continued the test of the remaining 1 patient. Due to the comprehensive judgement of a doctor considering the background unique to the patient, PPMX-T003 was administered at the increased dosage. The observation period is expected to finish in the end of July 2024. PPMX-T003 is an antibody targeting TfR1 that is related to iron intake into cells. TfR1 is highly expressed in cells that require much more iron than usual cells. Erythroblasts, which are nucleated cells in bone marrow from which RBCs derive, are one of them. When PPMX-T003 binds to TfR1, it inhibits cell proliferation by inhibiting iron uptake into erythroblasts. Therefore, it is expected to normalize the number of RBCs of PV patients, who have too many RBCs. TfR1 is also expressed in cancer cells that proliferate at a significant pace. PPMX-T003 similarly inhibits proliferation of cancer cells due to its function of inhibiting iron intake. Also, investigator-led phase I/II clinical trial of PPMX-T003 among aggressive NK-call leukemia (ANKL) patients is underway. New Risk • Apr 27
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 22% per year over the past 5 years. Revenue is less than US$1m (JP¥96m revenue, or US$608k). Minor Risks Shareholders have been diluted in the past year (4.0% increase in shares outstanding). Market cap is less than US$100m (JP¥4.21b market cap, or US$26.6m). Annuncio • Mar 07
Perseus Proteomics Inc. announced that it has received ¥1.566 million in funding from Barclays Bank PLC (Tokyo Branch) On March 7, 2024, Perseus Proteomics Inc. closed the transaction. Annuncio • Mar 02
Perseus Proteomics Inc. to Report Fiscal Year 2024 Results on May 15, 2024 Perseus Proteomics Inc. announced that they will report fiscal year 2024 results on May 15, 2024 Reported Earnings • Feb 16
Third quarter 2024 earnings released Third quarter 2024 results: Net loss: JP¥266.7m (loss widened 34% from 3Q 2023). Annuncio • Feb 02
Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera Perseus Proteomics Inc. announced that there will be a delay in the end of the Phase I clinical trial of PPMX-T003, an anti-transferrin receptor 1 (TfR1) antibody, among PV patients from the initial forecast of within the fiscal year ending March 31, 2024 to the end of June 2024. This trial primarily investigates the safety and pharmacokinetics in administering PPMX-T003 to 6 patients suffering from PV, a disease characterized by excess increase in red blood cells (RBCs). The secondary purpose is to confirm the therapeutic effects. The tests of the 4 patients have already ended and the Company has continued incremental administration of PPMX-T003 to the remaining 2 patients and follow-up observation. Due to the circumstances of the tests at the end of January, the observation period is to delay from the initial forecast. To be more concrete, administration to one patient was postponed due to circumstances and administration of the increased dosage to the other was decided. This trial is estimated to finish at the end of June 2024. Annuncio • Nov 30
Perseus Proteomics Inc. to Report Q3, 2024 Results on Feb 14, 2024 Perseus Proteomics Inc. announced that they will report Q3, 2024 results on Feb 14, 2024 Reported Earnings • Nov 14
Second quarter 2024 earnings released Second quarter 2024 results: Net loss: JP¥211.5m (loss widened 30% from 2Q 2023). Annuncio • Oct 21
Perseus Proteomics Inc. Announces Completion of Patients Enrollment in Phase I Clinical Trial for Polycythemia Vera (PV) Per Perseus Proteomics Inc. announced that the Company has completed enrollment of 6 patients in PPMX-T003, an anti-transferrin receptor 1 (TfR1) antibody, Phase I clinical trial among PV patients. This trial primarily investigates the safety and pharmacokinetics in administering PPMX-T003 to patients suffering from PV, a disease that causes production of red blood cells (RBCs) at an abnormal level. The secondary purpose is to confirm the therapeutic effects. The Company will administer PPMX-T004 to the newly enrolled patients and will finish the phase I clinical trial within the fiscal year 2023. There is no impact on the financial results forecast for the fiscal year 2023. About PPMX-T003: PPMX-T003 is an antibody targeting TfR1 that is related to iron intake into cells. TfR1 is highly expressed in cells that require much more iron than usual cells. Erythroblasts, which are nucleated cells in bone marrow from which RBCs derive, are one of them. When PPMX-T003 binds to TfR1, it inhibits cell proliferation by inhibiting iron uptake into erythroblasts. Therefore, it is expected to normalize the number of RBCs of PV patients, who have too many RBCs. TfR1 is also expressed in cancer cells that proliferate at a significant pace. PPMX-T003 similarly inhibits proliferation of cancer cells due to its function of inhibiting iron intake. Also, investigator-led phase I/II clinical trial of PPMX-T003 among aggressive NK-call leukemia (ANKL) patients is underway. Annuncio • Oct 11
Perseus Proteomics Inc. Announces Sales Launch of New Antibodies/Reagents Perseus Proteomics Inc. announced the sales launch of new antibodies/reagents: Anti-mAQP4 antibody (for reproducing symptoms of neuromyelitis optica in animal experiments, etc.). Anti-DOTA antibody (for measuring DOTA-bound antibodies concentration in blood in animal experiments or clinical trials, etc.). Anti-DM1 antibodyfor measuring ADC concentration in blood in animal experiments or clinical trials, etc.). The company provided various antibodies/reagents for researchers at academia or companies throughout the world. The company will provide various services to support research activities of academia and companies. Annuncio • Sep 28
Perseus Proteomics, Inc. Announces Provision of Antibody Research Support Service Through Single Cell Cloning Technology Perseus Proteomics Inc. announced that the Company has started to provide antibody research support service utilizing single cell cloning technology. The Company has been working on the antibody drug discovery through hybridoma technology and phage display technology, utilizing the unique phage library and the screening method. Now the Company has adopted single cell cloning technology as a new antibody obtaining method. The Company will not only utilize this technology in drug discovery business but also develop it as research support service for research and development by academia and companies. This service enables to obtain antibodies through isolating, screening, and selecting the cell that produces the target antibodies one by one without conventionally required processes including fusing cells and establishing libraries. The platform of the Company has been integrated with a high throughput device so that antibodies can be obtained speedily and efficiently. Also, this service is available for a wide variety of applications including analysis of single cell genes, retrieval of rare cells, and cell cloning after inserting genes. The impact on the fiscal year 2023 business results of the Company is minor. The Company will aim to provide various services to support research activities of academia and companies. Annuncio • Sep 23
Perseus Proteomics Inc. Announces on Dosing of the First Patient in Phase I/II Clinical Trial for Aggressive NK-Cell Leukemia Per Perseus Proteomics Inc. announced that the first patient has been dosed with PPMX-T003 in the Phase I/II investigator-led clinical trial for aggressive NK-cell leukemia (ANKL). This clinical trial has been prepared and performed under the support by AMED since April 2022 after adopted as Project Promoting Support for Drug Discovery Support Program for Orphan drug prior to the Designation. Its purpose is to assess the safety and tolerability in administering PPMX-T003 to ANKL patients, as well as efficacy and pharmacokinetics. ANKL is a rare refractory hematological malignancy, with a need to establish the effective standard treatment as soon as possible. PPMX-T003 is an antibody targeting transferrin receptor 1 (TfR1) that is related to iron intake into cells. TfR1 is highly expressed in hematopoietic cells that require much more iron than usual cells, as well as cancer cells. When PPMX-T003 binds to TfR1, it is expected to inhibit cancer cell proliferation by inhibiting iron uptake into cancer cells. The Company has been also conducting the phase I clinical trial of PPMX-T003 for polycythemia vera, where RBCs increase at an abnormal level. Annuncio • Sep 02
Perseus Proteomics Inc. to Report Q2, 2024 Results on Nov 13, 2023 Perseus Proteomics Inc. announced that they will report Q2, 2024 results on Nov 13, 2023 Reported Earnings • Aug 16
First quarter 2024 earnings released: JP¥35.89 loss per share (vs JP¥17.01 loss in 1Q 2023) First quarter 2024 results: JP¥35.89 loss per share (further deteriorated from JP¥17.01 loss in 1Q 2023). Net loss: JP¥422.0m (loss widened 111% from 1Q 2023). Annuncio • Jun 03
Perseus Proteomics Inc. to Report Q1, 2024 Results on Aug 14, 2023 Perseus Proteomics Inc. announced that they will report Q1, 2024 results on Aug 14, 2023 Annuncio • May 30
Perseus Proteomics Inc. Announces the Interim Report of Phase I Clinical Trial of PPMX-T003 Perseus Proteomics Inc. announced that the interim report of phase I clinical trial of PPMX-T003, its anti-transferrin receptor antibody, among polycythemia vera ("PV") patients was presented at the 118th Japanese Society of Hematology Kinki Association Meeting in Osaka on May 29, 2023. This is the interim report of phase I study in 6 PV patients. The results of 3 patients were almost in line with the results of phase I study among healthy volunteers (5 cohorts, total 40) B) No serious adverse events were seen in all the three patients and the same level of safety was confirmed as that among healthy volunteers. In case 1 and case 3, PPMX-T003 was administered at a dose of 0.25mg/kg, while dose escalated from 0.25mg/kg., 0.4mg/kg, to 0.64mg/kg in case 2. Before the phase I study, the three patients had been treated with phlebotomy every 4 to 9 weeks respectively. The study finished with confirmation that there was no need for phlebotomy for 12 weeks after administration in the three patients. As hematocrit and hemoglobin both decreased, it was also confirmed that administration of PPMX-T001 has a reducing effect on erythroblasts and red blood cells just like healthy volunteers. The detailed data on safety and promising treatment efficacy data were reported as well. Thus, it was shown that PPMX-T003 has a possibility to be an effective therapeutic drug against PV, a disease characterized by an excessive number of red blood cells. Reported Earnings • May 13
Full year 2023 earnings released Full year 2023 results: Net loss: JP¥787.0m (loss widened 31% from FY 2022). Annuncio • May 13
Perseus Proteomics Inc., Annual General Meeting, Jun 23, 2023 Perseus Proteomics Inc., Annual General Meeting, Jun 23, 2023. Reported Earnings • Feb 15
Third quarter 2023 earnings released: JP¥16.92 loss per share (vs JP¥10.12 loss in 3Q 2022) Third quarter 2023 results: JP¥16.92 loss per share (further deteriorated from JP¥10.12 loss in 3Q 2022). Net loss: JP¥199.0m (loss widened 67% from 3Q 2022). Annuncio • Feb 14
Perseus Proteomics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023 Perseus Proteomics Inc. provided consolidated earnings guidance for the Fiscal Year Ending March 31, 2023. For the period, the company expects net sales to be JPY 77 million, operating loss to be JPY 703 million, loss to be JPY 854 million, basic loss per share to be JPY 72.62. Annuncio • Feb 07
Perseus Proteomics Inc. Announces Extension of Phase I Clinical Trial of PPMX-T003 among Polycythemia Vera Patients Perseus Proteomics Inc. announced that it has extended the clinical trial period of a Phase I clinical trial of PPMX-T003 among polycythemia vera patients and that it now expects the completion of the Phase 1 in the fiscal year 2023 ending March 31, 2024, changed from the fiscal year 2022 ending March 31, 2023. This is because recruitment of the patients has delayed from the initial plan. Since the purpose of the Phase I is to evaluate safety, the Company has set PV patients who have using only phlebotomy as treatment, not anti-cancer drugs or other existing drugs, as participants in this Phase I. The number of such patients, however, is small. Besides, the Company has set several inclusion criteria such as low EPO (hormone to stimulate production of red blood cells) levels and PV diagnosis with significance on the WHO diagnostic criteria (performing bone marrow biopsy, etc.) at the same time. The Company, however, has found that such criteria do not reflect the clinical practice. For example, in several PV patients, high EPO levels are shown due to the influence of phlebotomy. Therefore, the Company has amended the inclusion criteria to promote recruitment of the patients. The Company has also been striving to add clinical trial locations: currently four locations have been registered. As a result, PPMX-T003 was administered to the first and second patients in August 2022, and to the third in February 2023. With regards to the remaining three patients, however, the administration timing is still unpredictable. Considering the circumstances, the Company has decided to extend the clinical trial period. So far, no major problem of safety has been reported from the three participants. The Company will aim at completion of the Phase I as early as possible through adding more clinical trial locations, which is already under a procedure. There is no impact on the business result forecasts for the fiscal year 2022. As for the fiscal year 2023, the Company is studying the impact carefully. Annuncio • Nov 27
Perseus Proteomics Inc. to Report Q3, 2023 Results on Feb 13, 2023 Perseus Proteomics Inc. announced that they will report Q3, 2023 results on Feb 13, 2023 Reported Earnings • Nov 16
Second quarter 2023 earnings released: JP¥13.86 loss per share (vs JP¥10.12 loss in 2Q 2022) Second quarter 2023 results: JP¥13.86 loss per share (further deteriorated from JP¥10.12 loss in 2Q 2022). Net loss: JP¥163.0m (loss widened 37% from 2Q 2022). Board Change • Nov 16
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 8 non-independent directors. Director Tatsuya Nagase was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Reported Earnings • Nov 13
Second quarter 2023 earnings released: JP¥13.86 loss per share (vs JP¥10.12 loss in 2Q 2022) Second quarter 2023 results: JP¥13.86 loss per share (further deteriorated from JP¥10.12 loss in 2Q 2022). Net loss: JP¥163.0m (loss widened 37% from 2Q 2022). Annuncio • Nov 12
Perseus Proteomics Inc. Provides Earnings Guidance for the Year Ending March 31, 2023 Perseus Proteomics Inc. provided earnings guidance for the year ending March 31, 2023. For the year, the company expects net sales of JPY 77 million, operating loss of JPY 703 million, loss of JPY 854 million or JPY 72.62 per basic share. Annuncio • Sep 02
Perseus Proteomics Inc. to Report Q2, 2023 Results on Nov 11, 2022 Perseus Proteomics Inc. announced that they will report Q2, 2023 results on Nov 11, 2022 Annuncio • Aug 25
Perseus Proteomics Inc. Announces First/Second Patients Dosed in Phase I Clinical Trial Among Polycythemia Vera (Pv) Patients Perseus Proteomics Inc. announce the first and second patients have been dosed PPMX-T003 in the Phase I clinical trial among PV patients. This trial will primarily investigate the safety and pharmacokinetics in administering PPMX-T003 to patients with PV, a disease where red blood cells (RBCs) multiply at an abnormal level. The secondary purpose is to confirm the therapeutic effects. In the recruitment of PV patients, the Company has amended the inclusion criteria to be closer to the real- world clinical practice after consultation with the investigators at the medical institutions. The Company expects the phase I clinical trial finishes within this fiscal year, as it has been preparing for the addition of medical institutions. Annuncio • Aug 13
Perseus Proteomics Inc. Provides Earnings Guidance for the Year Ending March 31, 2023 Perseus Proteomics Inc. provided earnings guidance for the year ending March 31, 2023. For the year, the company expects net sales of JPY 77 million, operating loss of JPY 703 million, loss of JPY 854 million or JPY 72.62 per basic share. Annuncio • Jun 02
Perseus Proteomics Inc. to Report Q1, 2023 Results on Aug 12, 2022 Perseus Proteomics Inc. announced that they will report Q1, 2023 results on Aug 12, 2022 Annuncio • May 14
Perseus Proteomics Inc., Annual General Meeting, Jun 23, 2022 Perseus Proteomics Inc., Annual General Meeting, Jun 23, 2022. Board Change • Apr 27
No independent directors There are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 9 non-independent directors. Director Takashi Ohno was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Annuncio • Apr 08
Perseus Proteomics Inc. to Report Fiscal Year 2022 Results on May 13, 2022 Perseus Proteomics Inc. announced that they will report fiscal year 2022 results on May 13, 2022 Annuncio • Feb 16
Perseus Proteomics Inc. Provides Earnings Guidance for the Year Ending March 31, 2022 Perseus Proteomics Inc. provided earnings guidance for the year ending March 31, 2022. For the year, the company expects net sales of JPY 70 million, operating loss of JPY 564 million, loss of JPY 625 million or JPY 57.16 per basic share. Annuncio • Sep 15
Perseus Proteomics Inc. Announces Initiation of Phase I Clinical Trial in Polycythemia Vera Patients Perseus Proteomics Inc. announced the initiation of the Phase I clinical trial among polycythemia vera patients with regards to the pipeline PPMX-T003, an anti-transferrin receptor antibody. The purpose of this trial is to confirm the safety and pharmacokinetics in administering PPMX-T003 to patients suffering from PV, a disease where red blood cells (RBCs) multiply at an abnormal level. The Company submitted the clinical trial notification to the PMDA on May 31, 2021, which was approved following the investigation. The Company has signed a contract between one of the hospitals where this trial will be implemented and expects administration to PV patients after registration. PPMX-T003 is an antibody targeting transferrin receptor (TfR) that is related to iron intake into cells. TfR is highly expressed in cells that require much more iron than usual cells: erythroblasts, which are nucleated cells in bone marrow from which RBCs derive, are one of them. When PPMX-T003 binds to TfR, it inhibits cell proliferation by inhibiting iron uptake into erythroblasts. Therefore, it is expected to normalize the number of RBCs of PV patients, who have too many RBCs. TfR is also expressed in cancer cells that proliferate at a significant pace. PPMX-T003 similarly inhibits proliferation of cancer cells due to its function of inhibition of iron intake. As PPMX-T003 is expected to have therapeutic effects for a wide variety of cancers including acute myeloma leukemia (AML), its development has been the main focus of the Company. 